Every day, we witness the financial rollercoaster ride of analyst upgrades and downgrades, often accompanied by price targets. For investors, these announcements serve as a roadmap, injecting a shot of positivity into the veins of future performance. Indeed, stocks don’t move in a straight line towards these targets – unforeseen circumstances can always throw a spanner in the works. Nevertheless, the prevailing sentiment shift due to these upgrades is hard to miss.
AbbVie: An Earnings Performer
A shining example of this recently is AbbVie (ABBV). William Blair upgraded AbbVie shares to Outperform with a fresh $190 per share price target, suggesting a generous 15% upside from current levels. This boost came in the run-up to the company’s next quarterly release, expected on Friday, February 2nd.
AbbVie has been consistently outperforming earnings wise, surpassing revenue and EPS expectations in its last three releases. The latest impressive results were driven by a robust performance across its non-Humira growth platform, prompting the company to raise its guidance for FY23.
The company’s shareholder-friendly nature is not to be underestimated, holding a coveted position in the elite Dividend Aristocrats club. ABBV shares currently offer a solid 3.8% annual yield, coupled with a sustainable payout ratio of 50% of its earnings.
While it’s true that shares trade at a premium relative to historical levels, the current 14.5X forward 12-month earnings multiple is still below the industry average of 18.9X.
Hershey: Sweet Future Growth
Then there’s Hershey (HSY). Bernstein upgraded Hershey shares to Outperform, setting a $235 price target that suggests over 20% upside from current levels. Despite a 12% decline over the past year, underperforming the market, Hershey boasts a shareholder-friendly stance, currently sporting a 10% five-year annualized dividend growth rate.
The company’s steady growth momentum is anticipated to continue, with consensus expectations for the current year pointing to 12% earnings growth on 8% higher sales. Looking ahead to FY24, estimates indicate an additional 3% bottom line expansion paired with a 2.9% sales increase.
Dollar Tree: Growing Stronger
Lastly, Dollar Tree (DLTR) has also received a nod from analysts, as JPMorgan upgraded it to Overweight and raised its price target to $157 per share, signaling an 18% upside from current levels. Despite a modest relative strength display over the last three months, with a 21% increase compared to the S&P 500’s robust 18% gain, consensus expectations for its next quarterly release suggest solid growth.
Earnings are projected to climb 13% year-over-year on 12% improved sales. Analysts’ optimism for the release can be seen in the 3% boost to the $2.66 Zacks Consensus EPS Estimate since November.
In Conclusion
Price targets are undeniably useful aids. While it’s important to remember that not all stocks reach these forecasted levels due to unforeseen circumstances, the positive aura surrounding these upgrades is hard to ignore. For those in search of stocks that have recently received favorable analyst coverage, AbbVie (ABBV), Hershey (HSY), and Dollar Tree (DLTR) certainly fit the bill.
7 Best Stocks for the Next 30 Days
Just released: Experts have distilled 7 top stocks from the current list of 220 Zacks Rank #1 Strong Buys, deeming them “Most Likely for Early Price Pops.”
Since 1988, the full list has beaten the market by more than 2X with an average gain of +24.0% per year. So, be sure to give these hand-picked 7 your immediate attention.
Dollar Tree, Inc. (DLTR) : Free Stock Analysis Report
Hershey Company (The) (HSY) : Free Stock Analysis Report
AbbVie Inc. (ABBV) : Free Stock Analysis Report
To read this article on Zacks.com click here.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
